Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.38 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.36 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15170264 | 0.87 | PTGES (0.41) | PTGESERCC1ERCC4GAACDK5 | |
| SCHEMBL15540181 | 0.83 | CDK5 (0.40) | PTGESERCC1ERCC4GAACDK5 | |
| SCHEMBL15540053 | 0.82 | CYP1A2 (0.40) | EPHX2NR1H4HPGDCYP1A2CYP2C19 | |
| SCHEMBL15540132 | 0.81 | PTGES (0.37) | PTGESERCC1ERCC4GAACDK5 | |
| SCHEMBL15541104 | 0.81 | ERCC1 (0.38) | PTGESERCC1ERCC4GAACDK5 | |
| SCHEMBL15540481 | 0.76 | LMNA (0.44) | PTGESCA1CA2HPGDSMN1; SMN2 | |
| SCHEMBL15170042 | 0.75 | PTGES (0.42) | PTGESERCC1ERCC4GAAPOLB | |
| SCHEMBL15540923 | 0.75 | ERCC1 (0.36) | PTGESERCC1ERCC4GAACDK5 | |
| SCHEMBL15170572 | 0.73 | GAA (0.46) | PTGESERCC1ERCC4GAAPOLB | |
| SCHEMBL3333144 | 0.71 | POLB (0.52) | POLBAPEX1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10821100-B2 | Triazolone compounds as mPGES-1 inhibitors | Ichnos Sciences SA (CH) | 2020-11-03 | — | — | US | disclosed |
| US-10821100-B2 | Triazolone compounds as mPGES-1 inhibitors | Ichnos Sciences SA (CH) | 2020-11-03 | — | — | US | disclosed |
| US-20190282548-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2019-09-19 | — | — | US | disclosed |
| US-20190282548-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2019-09-19 | — | — | US | disclosed |
| US-10391083-B2 | Triazolone compounds as MPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A (CH) | 2019-08-27 | — | — | US | disclosed |
| US-10391083-B2 | Triazolone compounds as MPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A (CH) | 2019-08-27 | — | — | US | disclosed |
| US-20180200229-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2018-07-19 | — | — | US | disclosed |
| US-20180200229-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2018-07-19 | — | — | US | disclosed |
| US-9949955-B2 | Triazolone compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-04-24 | — | — | US | disclosed |
| US-9949955-B2 | Triazolone compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-04-24 | — | — | US | disclosed |
| EP-2718284-B1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS SA (CH) | 2015-11-18 | — | — | EP | disclosed |
| US-20150283117-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2015-10-08 | — | — | US | disclosed |
| US-20150283117-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2015-10-08 | — | — | US | disclosed |
| US-9096545-B2 | Triazolone compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-08-04 | — | — | US | disclosed |
| US-9096545-B2 | Triazolone compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-08-04 | — | — | US | disclosed |
| US-20150087646-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-03-26 | — | — | US | disclosed |
| US-20150087646-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-03-26 | — | — | US | disclosed |
| EP-2718284-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | Glenmark Pharmaceuticals S.A. (CH) | 2014-04-16 | — | — | EP | disclosed |
| WO-2013186692-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-12-19 | — | — | WO | disclosed |
| WO-2013186692-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150283117-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | PTGES, PTGIS, PTGS1 | PTGES 1/4885ERCC1 3867/4885ERCC4 3625/4885 |
| US-20190282548-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | PTGES, PTGS1, PTGIS | PTGES 1/4885ERCC1 4040/4885ERCC4 3711/4885 |
| US-10391083-B2 | Triazolone compounds as MPGES-1 inhibitors | PTGES, PTGS1, PTGIS | PTGES 1/4885ERCC1 4040/4885ERCC4 3711/4885 |
| US-20180200229-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | PTGES, PTGS1, PTGIS | PTGES 1/4885ERCC1 4040/4885ERCC4 3711/4885 |
| US-20150087646-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | PTGES, PTGS1, PTGIS | PTGES 1/4885ERCC1 4040/4885ERCC4 3711/4885 |
| US-10821100-B2 | Triazolone compounds as mPGES-1 inhibitors | PTGES, PTGS1, PTGIS | PTGES 1/4885ERCC1 4040/4885ERCC4 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.